Fredun Pharmaceuticals Limited (BOM:539730)
India · Delayed Price · Currency is INR | Market Cap | 13.59B +326.9% |
| Revenue (ttm) | 5.91B +45.6% |
| Net Income | 326.79M +73.8% |
| EPS | 70.40 +74.5% |
| Shares Out | 5.51M |
| PE Ratio | 35.01 |
| Forward PE | n/a |
| Dividend | 0.70 (0.03%) |
| Ex-Dividend Date | Sep 23, 2025 |
| Volume | 12,646 |
| Average Volume | 11,205 |
| Open | 2,545.00 |
| Previous Close | 2,512.60 |
| Day's Range | 2,412.30 - 2,548.00 |
| 52-Week Range | 666.00 - 2,548.00 |
| Beta | 0.68 |
| RSI | 79.83 |
| Earnings Date | May 26, 2026 |
About Fredun Pharmaceuticals
Fredun Pharmaceuticals Limited manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, and other healthcare products in India, Africa, Southeast Asia, Commonwealth of Independent States countries, MENA region, and Latin America. The company offers allopathic formulations, including analgesics/NSAID, antacid/antiulcer, anthelmintic, anti-bacterial, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, antacid, anthelmintic, antibacterial, analgesics, anti-diabetic, anti-inflammatory, anti-malarial... [Read more]
Financial Performance
In fiscal year 2025, Fredun Pharmaceuticals's revenue was 4.54 billion, an increase of 30.35% compared to the previous year's 3.48 billion. Earnings were 197.39 million, an increase of 26.34%.
Financial StatementsNews
Fredun Pharmaceuticals Ltd (BOM:539730) Q3 2026 Earnings Call Highlights: Strong Growth and ...
Fredun Pharmaceuticals Ltd (BOM:539730) Q3 2026 Earnings Call Highlights: Strong Growth and Strategic Expansion
Q3 2026 Fredun Pharmaceuticals Ltd Earnings Call Transcript
Q3 2026 Fredun Pharmaceuticals Ltd Earnings Call Transcript
Fredun Pharmaceuticals Transcript: Q3 25/26
Q3 and nine-month FY26 saw strong revenue and profit growth, with significant margin expansion. Legacy business grew 15–20% YoY, while New Age segments like pet care and mobility are scaling rapidly. No immediate funding needs are anticipated, and margins are expected to improve as new brands mature.
Fredun Pharmaceuticals Ltd (BOM:539730) Q2 2026 Earnings Call Highlights: Robust Growth and ...
Fredun Pharmaceuticals Ltd (BOM:539730) Q2 2026 Earnings Call Highlights: Robust Growth and Strategic Expansions
Q2 2026 Fredun Pharmaceuticals Ltd Earnings Call Transcript
Q2 2026 Fredun Pharmaceuticals Ltd Earnings Call Transcript
Fredun Pharmaceuticals Transcript: Q2 25/26
Strong Q2 and H1 FY26 results with double-digit revenue and profit growth, driven by expansion in pet care, nutraceuticals, and mobility. Strategic acquisitions and manufacturing expansion support long-term growth, with positive cash flow and robust guidance for the coming years.
Fredun Pharmaceuticals Transcript: Q1 25/26
Q1 FY 2026 saw revenue rise 52% and net profit 64% year-on-year, driven by strong branded generics and pet care growth. The company targets to double revenue and PAT in 3-4 years, with new age business expected to contribute over half of future revenue.
Fredun Pharmaceuticals stock jumps 3% after company set to launch advanced functional foods plant
Fredun Pharmaceuticals Limited saw a 3% jump in its stock price following the announcement of its new cutting-edge functional foods manufacturing facility. Located in Palghar, Maharashtra, this state-...